The International Osteoporosis Foundation (IOF) has honored Dr. Thierry Chevalley, Associate Professor at the Faculty of Medicine, University of Geneva,…
Amivantamab, a bispecific monoclonal antibody designed to target both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), has…
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible…
In the realm of natural history and biomechanics, an intriguing revelation challenges long-standing beliefs about the origins of certain morphological…